Otros idiomas Swedish Orphan Biovitrum AB

Acciones

SOBI

SE0000872095

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:30 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
282,4 ^SEK	+1,66 %		+0,79 %	+5,77 %

28/05	BerGenBio ASA firma un acuerdo de ensayo clínico con el Centro Oncológico Mays del Centro de Ciencias de la Salud de la Universidad de Texas en San Antonio y con Swedish Orphan Biovitrum AB	CI
14/05	Swedish Orphan Biovitrum AB (publ) elige a Zlatko Rihter como nuevo miembro del Consejo	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB	28/05
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member	14/05
Sobi Finalizes Inaugural SEK3 Billion Bond Issue	08/05
Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy	08/05
Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	26/04
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	26/04
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	26/04
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024	25/04
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	25/04
OPINIONES DE LOS ANALISTAS DEL DÍA : Inditex, Acciona Energia, Merlin Properties, Tod's, Euronext, ...	22/02
Sobi to Expand in South Korea via Rare Disease JV with Handok	13/02
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	12/02
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	12/02
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	09/02
Transcript : Swedish Orphan Biovitrum AB, Q4 2023 Earnings Call, Feb 08, 2024	08/02
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	08/02
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	02/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Swedish Orphan Biovitrum AB

Acciones

SOBI

SE0000872095

Otros idiomas

Filtros